Moolec Science SA (MLEC)

Moolec Science SA Regains Compliance with All Nasdaq Capital Market Continued Listing Requirements Within Panel Remediation PeriodMay 13, 2026 6:35 PM
ACCESS NewswireGEORGE TOWN, CAYMAN ISLANDS / ACCESS Newswire / May 13, 2026 / As previously reported on January 29, 2026, Moolec Science SA ("Moolec" and/or the "Company"), received written notice from the Nasdaq Hearings Panel (the "Panel") informing the Company that the Panel had granted the Company's request for an extension to regain compliance with the continued listing requirements of The Nasdaq Stock Market LLC, specifically with respect to the minimum stockholders' equity requirement.The Company announced today that it has submitted information required to demonstrate compliance with the Nasdaq Capital Market's stockholders' equity requirement within the remediation period granted by the Panel. The Company reported stockholders' equity of approximately $11.3 million as of March 31, 2026, and approximately $15.2 million as of December 31, 2025. These amounts are reflected in the Company's unaudited interim condensed consolidated financial statements as of December 31, 2025 and June 30, 2025, and for the six-month periods ended December 31, 2025 and 2024, furnished today to the U.S. Securities and Exchange Commission ("SEC") on Form 6-K, as well as in the Company's unaudited preliminary balance sheet as of March 31, 2026 set forth below.Preliminary Consolidated Condensed Balance Sheet as of March 31, 2026
(Unaudited) Unaudited historical financial informationMLECas of December 31, 2025 Unaudited preliminary financial informationMLECas of March 31, 2026 (amounts in millions of US$) Assets Intangible assets 71.6 71.6 Goodwill 2.1 2.1 Property, plant and equipment 4.4 4.4 Investment in joint ventures and associates 16.0 16.0 Cash and cash equivalents 1.0 1.2 Inventories 4.0 3.6 Other receivables 4.2 5.2 Right of use assets 0.1 - Total assets 103.4 104.2 Equity Total equity 15.2 11.3 Liabilities Borrowings 45.7 50.6 Convertible notes 20.7 21.0 Trade and other payables 7.1 7.2 Other liabilities 0.3 0.3 Deferred tax liabilities 14.3 14.3 Warrant liabilities 0.1 0.3 Lease liabilities 0.1 - Total liabilities 88.2 93.4 Total equity and liabilities 103.4 104.7 Underlying AssumptionsDerecognition EventsThe Company assumed the full derecognition of Bioceres S.A. and Bioceres LLC as of December 31, 2025 and determined that the carrying value of the Company's investment in Theo I SCSp was nil.Preference Shares CapitalizationThe holder of our preference shares issued a notice of conversion to the Company dated December 31, 2025, notifying the Company of the partial exercise of its conversion right under the Subscription Agreement dated December 9, 2024 an aggregate amount of up to $9,000,000, to be converted into ordinary shares in accordance with the conversion formula set out in the Subscription Agreement. The Company notified the holder of the preference shares on December 31, 2025 that the value of the ordinary shares to be issued to the holder as a result of such conversion would be $5,000,000, plus payment-in-kind, for an aggregate amount of $5,473,425. This equity transaction has been reflected in the column "Unaudited historical financial information MLEC as of December 31, 2025" of the table above.The Company also included as of March 31, 2026 the proforma adjustment related to disbursements made from our current line of credit with one of our related parties for an amount of $465,161 which occurred in April 2026.Furthermore, the Company expects to notify the holder to convert the remaining $4.0 million of the original aggregate preference share amount within the next 12 months, which is expected to further strengthen stockholders' equity.Forward-looking StatementsThis press release contains "forward-looking statements." Forward-looking statements may be identified by the use of words such as "forecast," "intend," "seek," "target," "anticipate," "believe," "expect," "estimate," "plan," "outlook," and "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements with respect to the Company's plan to regain compliance under the Nasdaq rules and the related Nasdaq decision, performance, prospects, revenues, and other aspects of the business of Moolec are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors, about which we cannot be certain. We cannot assure you that the forward-looking statements in this press release will prove accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, changes in applicable laws or regulations, the possibility that Moolec may be adversely affected by economic, business and/or other competitive factors, costs related to the scaling up of Moolec's business and other risks and uncertainties, including those included under the header "Risk Factors" in Moolec's Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission ("SEC"), as well as Moolec's other filings with the SEC. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, you should not put undue reliance on these statements.Moolec Science's Contacts:compliance@moolecscience.comSOURCE: Moolec ScienceView the original press release on ACCESS NewswireOriginal: Moolec Science SA Regains Compliance with All Nasdaq Capital Market Continued Listing Requirements Within Panel Remediation Period

Moolec Science Confirms Completion of First Phase of GLASO Industrialization Following Record 2025 Campaign; Advances 2026 Sowing and Expands Into Energy ApplicationsApril 29, 2026 9:03 AM
ACCESS NewswireWARWICK, UK / ACCESS Newswire / April 29, 2026 / Moolec Science Limited, a wholly-owned subsidiary of Moolec Science SA (NASDAQ:MLEC) ("the Company"; "Moolec"), an innovation-driven company engineering plants and microbes to unlock scalable protein solutions for the global food industry, today announced the successful completion of the first phase of industrialization of its GLASO1 safflower platform, following a 2025 campaign that materially exceeded all internal forecasts.Building on previously reported results confirming approximately 45% GLA ("Gamma-linolenic acid") concentration at commercial scale, the Company has now validated not only agronomic and processing performance, but also the industrial-scale handling and availability of high-purity GLA output, marking a critical step toward full commercial deployment.Industrialization Milestone AchievedThe 2025 GLASO1 campaign delivered a tremendous volume of high-purity GLA output, surpassing expected yields and enabling Moolec to successfully complete the initial phase of industrialization, including large-scale harvesting, logistics coordination, and integration with downstream industrial processes.This scale has translated into available, ready-for-delivery end product, reinforcing the Company's transition from development to commercialization. While initial market traction has been centered in the pet food industry, the quality, traceability, and concentration profile of GLASO1-derived oils position the platform to expand into higher-value applications, including the human nutrition and dietary supplements markets, where demand for molecular farming-derived, high-performance functional lipids continues to grow.GLASO1 2026 Campaign UnderwayWith this foundation in place, Moolec is advancing the GLASO1 2026 campaign, with sowing scheduled to begin in early May, continuing its disciplined, execution-led scaling strategy across existing U.S. agricultural infrastructure.Advancing Next-Generation Safflower PlatformsIn parallel, Moolec continues to expand its safflower innovation pipeline through a strategic research collaboration with one of the largest global agribusiness and food companies, as previously disclosed by the Company.As part of this initiative, Moolec has accessed a germplasm library of 386 safflower varieties sourced from Australia and is currently in the final phase of selecting the top candidate varieties based on performance, adaptability, and industrial potential.This program is expected to underpin the development of a new business unit focused on renewable energy feedstocks, targeting one of the largest and structurally growing global markets within the energy transition. While traditional approaches have been characterized by commodity dynamics, Moolec's strategy is differentiated, focusing on high-performance and scalable feedstocks."The 2025 campaign not only confirmed leading GLA concentrations, but also delivered a level of output that exceeded all expectations. Our focus now is clear: complete the industrialization pathway, scale through the 2026 campaign, and expand the platform into new verticals," said Alejandro Antalich, CEO of Moolec Science."By leveraging our molecular farming platform and selecting top-performing safflower varieties at scale, we are positioning Moolec at the highest-value layer of the value chain, where performance, traceability, and scalability drive premium economics. This approach enables participation across multiple high-value applications, including nutrition, supplements, and specialty ingredients, while also positioning the Company for long-term participation in energy markets," concluded Antalich.About Moolec Science SAMoolec Science is an innovation-driven company engineering plants and microbes to unlock scalable protein solutions for the global food system. By integrating Molecular Farming and precision fermentation, Moolec combines the cost efficiency of crops with the functionality and nutrition of animal proteins, creating sustainable and commercially viable ingredients. The Company's diversified pipeline includes alternative proteins, bioactive compounds, nutritional oils, and biological inputs for regenerative agriculture. Moolec has a robust intellectual property portfolio with more than 50 granted and patent applications across multiple technology platforms. With operations spanning the United States, Europe and South America, Moolec is advancing a seed-to-ingredient approach designed to transform the future of food production. Moolec is publicly listed on Nasdaq under the ticker "MLEC." For more information, please contact Investor Relations at ir.moolecscience.com.Forward Looking StatementsThis press release contains "forward-looking statements." Forward-looking statements may be identified by the use of words such as "forecast," "intend," "seek," "target," "anticipate," "believe," "expect," "estimate," "plan," "outlook," and "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements with respect to performance, prospects, revenues, and other aspects of the business of Moolec are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors, about which we cannot be certain. We cannot assure you that the forward-looking statements in this press release will prove accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, changes in applicable laws or regulations, the possibility that Moolec may be adversely affected by economic, business and/or other competitive factors, costs related to the scaling up of Moolec's business and other risks and uncertainties, including those included under the header "Risk Factors" in Moolec's Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission ("SEC"), as well as Moolec's other filings with the SEC. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, you should not put undue reliance on these statements.Moolec Science's Contacts:Investor Relations inquiries:
ir@moolecscience.com¹ Pat. US 7,893,321 B2 (Application No. 11/438,951) and Pat. US 8,192,964 B2 (Application No. 13/025,345)SOURCE: Moolec ScienceView the original press release on ACCESS NewswireOriginal: Moolec Science Confirms Completion of First Phase of GLASO Industrialization Following Record 2025 Campaign; Advances 2026 Sowing and Expands Into Energy Applications

MLEC, will bounce back to $20's soon.

2026-02-19, MLEC, $23.22, Vol. 3,026,229 shares.

This Is Why Moolec Science Stock (MLEC) Rocketed Today

Feb 13, 2026

Moolec Science MLEC +66.47% ? stock underwent a massive rally on Friday after the science-based ingredient company announced positive results from the crushing process of its U.S. GLASO1 safflower platform. The results confirmed gamma-linolenic acid concentrations of roughly 45%. The company noted that this is a major operational milestone in its quest to develop scalable protein solutions for the global food industry.

Moolec Science noted that the results from its tests show that its GLASO1 program is compatible with standard U.S. crushing operations. The company said that this confirms that its GLASO1 program has the potential for commercial use in the U.S. Moolec Science also highlighted support from its U.S. partners for its GLASO1 program.

Alejandro Antalich, CEO of Moolec Science, said, “We believe the approximately 45% GLA concentration achieved by GLASO1 places it among the highest-performing GLA-producing platforms reported at commercial scale. This achievement reflects disciplined execution and close collaboration with best-in-class U.S. operators across the agricultural and processing value chain.”

Moolec Science Stock Movement Today
Moolec Science stock was up 113.33% in pre-market trading on Friday, following a 2% rally yesterday. The shares have also increased 33.58% year-to-date, but were down 95.03% over the past 12 months.

With today’s news came heavy trading of MLEC stock, as some 14 million shares changed hands this morning. For comparison, the stock’s three-month daily average trading volume is about 209,000 units.

Is Moolec Science Stock a Buy, Sell, or Hold?
Turning to Wall Street, analyst coverage of Moolec Science is lacking. Fortunately, TipRanks’ AI analyst Spark has it covered. Spark rates MLEC stock as Neutral (42) with a $5 price target. It cites “weak financial performance (large losses, cash burn, negative equity and higher debt) and bearish technicals (below key moving averages with negative MACD)” as reasons for this stance.

https://www.tipranks.com/news/this-is-why-moolec-science-stock-mlec-rocketed-today

$MLEC 🗞️

Moolec Science Achieves One of the Highest Commercial-Scale GLA Concentrations From U.S. GLASO1 CrushingFebruary 13, 2026 8:00 AM
ACCESS NewswireWARWICK, UK / ACCESS Newswire / February 13, 2026 / Moolec Science Limited, a wholly-owned subsidiary of Moolec Science SA (NASDAQ:MLEC)("the Company"; "Moolec"), an innovation-driven company engineering plants and microbes to unlock scalable protein solutions for the global food industry, today announced positive results from the crushing process of its U.S. GLASO1 safflower platform, confirming gamma-linolenic acid ("GLA") concentrations of approximately 45%. The results follow the successful completion of Moolec's 2025 U.S. GLASO1 safflower campaign and represent a major operational milestone, validating the Company's ability to deliver commercial-scale agricultural and industrial performance through its plant-engineered molecular farming platform.Crushing Results Confirm Commercial-Scale Performance
Following harvest, safflower produced under the GLASO1 program was processed through standard U.S. crushing operations. Analysis confirmed:~45% GLA concentrationCompatibility with existing U.S. agricultural and industrial infrastructureThese results confirm that the GLASO1 platform performs reliably through the crushing stage at commercial scale, a critical validation step for scalable ingredient production.2025 GLASO1 U.S. Campaign Highlights1,100 acres of engineered safflower cultivated across the United StatesAverage yield of approximately 2,200 lbs/acre, up from ~1,400 lbs/acre in 202457% year-over-year yield increaseHarvest performance materially exceeded internal forecastsThe 2025 campaign marked Moolec's first successful large-scale expansion of the GLASO1 platform, transitioning from prior development and smaller-scale deployments to full commercial agricultural execution.Strategic Positioning in the U.S. Nutrition & Supplements Market
The high GLA concentration achieved through the GLASO1 platform significantly strengthens Moolec's positioning in the U.S. nutrition and dietary supplements market, where demand favors:High-concentration functional lipidsPlant-engineered, traceable ingredientsScalable production systems aligned with existing infrastructureEarly engagement with U.S.-based market participants supports the Company's strategy of disciplined, execution-led growth anchored in validated performance rather than speculative scale-up."The U.S. GLASO1 platform has reached an inflection point," said Alejandro Antalich, CEO at Moolec Science. Achieving approximately 45% GLA concentration at commercial scale confirms that our technology is not only scientifically differentiated, but operationally executable within existing U.S. agricultural and processing infrastructure.""We believe the approximately 45% GLA concentration achieved by GLASO1 places it among the highest-performing GLA-producing platforms reported at commercial scale. This achievement reflects disciplined execution and close collaboration with best-in-class U.S. operators across the agricultural and processing value chain. Together, we have successfully validated acreage expansion, harvest performance, and crushing operations at scale. Our focus now is to build on this foundation through disciplined growth and the conversion of this operational advantage into sustainable, recurring revenue," concluded Antalich.Execution-Led Growth Strategy
Moolec continues to prioritize:Scaling platforms with demonstrated, repeatable performanceLeveraging existing U.S. agricultural infrastructureMaintaining strict cost and capital disciplineCommunicating progress through execution-driven milestonesThe Company views the 2025 U.S. GLASO1 campaign and subsequent crushing results as a foundational step toward repeatable commercial-scale production and long-term value creation.About Moolec Science SA
Moolec Science is an innovation-driven company engineering plants and microbes to unlock scalable protein solutions for the global food system. By integrating Molecular Farming and precision fermentation, Moolec combines the cost efficiency of crops with the functionality and nutrition of animal proteins, creating sustainable and commercially viable ingredients. The Company's diversified pipeline includes alternative proteins, bioactive compounds, nutritional oils, and biological inputs for regenerative agriculture. Moolec has a robust intellectual property portfolio with more than 118 granted and pending patents across multiple technology platforms. With operations spanning the United States, Europe and South America, Moolec is advancing a seed-to-ingredient approach designed to transform the future of food production. Moolec is publicly listed on Nasdaq under the ticker "MLEC." For more information, please visit www.moolecscience.com and ir.moolecscience.com.Forward Looking Statements
This press release contains "forward-looking statements." Forward-looking statements may be identified by the use of words such as "forecast," "intend," "seek," "target," "anticipate," "believe," "expect," "estimate," "plan," "outlook," and "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements with respect to performance, prospects, revenues, and other aspects of the business of Moolec are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors, about which we cannot be certain. We cannot assure you that the forward-looking statements in this press release will prove accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, changes in applicable laws or regulations, the possibility that Moolec may be adversely affected by economic, business and/or other competitive factors, costs related to the scaling up of Moolec's business and other risks and uncertainties, including those included under the header "Risk Factors" in Moolec's Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission ("SEC"), as well as Moolec's other filings with the SEC. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, you should not put undue reliance on these statements.Moolec Science's Contacts:
Investor Relations inquiries: ir@moolecscience.com¹ Pat. US11/438,951 and US13/025,345SOURCE: Moolec ScienceView the original press release on ACCESS NewswireOriginal: Moolec Science Achieves One of the Highest Commercial-Scale GLA Concentrations From U.S. GLASO1 Crushing

Moolec Science Granted Continued Listing on Nasdaq Subject to Hearings Panel ConditionsJanuary 30, 2026 4:20 PM
ACCESS NewswireGEORGE TOWN, CAYMAN ISLANDS / ACCESS Newswire / January 30, 2026 / Moolec Science S.A. ("Moolec" or the "Company"), a science-based food ingredient company focused on scalable protein solutions for the global market, today announced that the Nasdaq Hearings Panel (the "Panel") has granted the Company's request for continued listing on The Nasdaq Stock Market, subject to certain conditions.The Panel acknowledged that the Company satisfied the minimum bid price compliance period under Nasdaq Listing Rule 5550(b)(2) on January 16, 2026, following the effectiveness of its reverse stock split on January 5, 2026. The Panel will retain jurisdiction over the bid price matter through May 13, 2026, in accordance with its discretionary authority.The Panel also noted that the Company filed its Annual Report on Form 20-F for the fiscal year ended June 30, 2025 on December 29, 2025, shortly following the hearing held on December 18, 2025.With respect to the minimum stockholders' equity requirement under Nasdaq Listing Rule 5550(b)(1), the Panel recognized that the Company has presented a plan that offers a reasonable expectation of regaining compliance within the applicable period.The continued listing determination is subject to the Company satisfying certain conditions, including (i) the provision of updates to the Panel regarding the status of derecognition proceedings by the end of February 2026, (ii) the delivery of updated pro forma financial information by the end of March 2026, (iii) the timely public disclosure of actions taken to demonstrate compliance with Nasdaq's equity and continued listing requirements by May 13, 2026 and (iv) the Company's demonstration, on or before May 13, 2026, of compliance with all continued listing requirements for the Nasdaq Capital Market.Moolec intends to fully satisfy the conditions outlined in the Panel's decision and remains focused on maintaining sustained compliance with Nasdaq's continued listing standards, strengthening its financial framework and advancing its strategic priorities.About Moolec Science SAMoolec Science is an innovation-driven company engineering plants and microbes to unlock scalable protein solutions for the global food system. By integrating Molecular Farming and precision fermentation, Moolec combines the cost efficiency of crops with the functionality and nutrition of animal proteins, creating sustainable and commercially viable ingredients. The Company's diversified pipeline includes alternative proteins, bioactive compounds, nutritional oils, and biological inputs for regenerative agriculture. Moolec has a robust intellectual property portfolio with more than 118 granted and pending patents across multiple technology platforms. With operations spanning the United States, Europe and South America, Moolec is advancing a seed-to-ingredient approach designed to transform the future of food production. Moolec is publicly listed on Nasdaq under the ticker "MLEC." For more information, please visit www.moolecscience.com and ir.moolecscience.com.Forward-looking StatementsThis press release contains "forward-looking statements." Forward-looking statements may be identified by the use of words such as "forecast," "intend," "seek," "target," "anticipate," "believe," "expect," "estimate," "plan," "outlook," and "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements with respect to the Company's plan to regain compliance under the Nasdaq rules, performance, prospects, revenues, and other aspects of the business of Moolec are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors, about which we cannot be certain. We cannot assure you that the forward-looking statements in this press release will prove accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, changes in applicable laws or regulations, the possibility that Moolec may be adversely affected by economic, business and/or other competitive factors, costs related to the scaling up of Moolec's business and other risks and uncertainties, including those included under the header "Risk Factors" in Moolec's Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission ("SEC"), as well as Moolec's other filings with the SEC. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, you should not put undue reliance on these statements.Contact: ir@moolecscience.com (+5493412034927)SOURCE: Moolec ScienceView the original press release on ACCESS NewswireOriginal: Moolec Science Granted Continued Listing on Nasdaq Subject to Hearings Panel Conditions

Are you looking for me dirtbag? I'm here watching your $12 monster Tank a lot more baaaaaah 😂. How many shares you dump on your followers here? Asking for a friend 😂

Are you looking for me dirtbag? I'm here watching your $12 monster Tank a lot more baaaaaah 😂. How many shares you dump on your followers here? Asking for a friend 😂

The only monster is the pumper dumper cockroach 🪳🪳 Trend Trade of 2026 😂

The only monster is the pumper dumper cockroach 🪳🪳 Trend Trade of 2026 😂

Like I said maggot. Big dump coming. Down 2 bucks already 😂.

Like I said maggot. Big dump coming. Down 2 bucks already 😂.

Like I said maggot. Big dump coming. Down 2 bucks already 😂.

MLEC 12.57 high monster

IPW Breaking out 400k Float

MLEC breaks 10,00 monster

MLEC breaks 10,00 monster

MLEC monster of the day

MLEC monster

MLEC here we go

MLEC here we go

MLEC post rs monster

MLEC post RS ready to beast

MLEC...............................................................p/m

"SOYLENT GREEN IS PEOPLE" Sorry couldn't help myself. To da moon

Thank you for sharing!

MLEC: Whelp, now we find out just how REVOLUTIONARY their news was today!!

You are correct about that last sentence
Rule 1 always follow the rules
Rule 2 know when to break the rules

great one! how do you judge such a bounce as "more to come"? somebody in the know frontran news.
Most bounces off of 52w lows become new 52w lows?

About 3pm in Luxemborg

Early Barchart 100

https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc

MLEC: Let's all toast Champaign on Jupiter later today!!!

Ownership is practically al retail per TD Ameritrade
Next day settlement begins 5/28

How high can this go? Might be an absolute banger.

Mooooooo!

Damn

Moolec Science SA NASDAQ: MLEC

GoSymbol lookup
Consumer Staples : Food Products | | Based in LuxembourgCompany profile
Moolec Science SA is a science-based food ingredient company. The Company focuses on developing real animal proteins in plants using Molecular Farming, which is a sustainable technology. It operates in the United States, Europe, and South America. The Company's technology allows it to include animal proteins' gene deoxyribonucleic acid (DNA) codes inside the genome of the main plants used in food. Each protein is selected to add value in terms of targeted functionality, such as taste, texture, and nutritional values.

THIS IS EXCELLENT!

Whoops I did it again

Nice

high volume
insider own 90%, free float 3.5mln

This stock is one of a increasing number of stocks making new 52 week lows that bounced pretty good
The mature companies in April have declined
They’ll be back

MLEC new 52 lo

MLEC 10Q due March 13

MLEC new 52 week low

MLEC new 52=week low

MLEC new 52 week low

MLEC: Very pleased that I grabbed some of this puppy early today!!

MLEC is doing it again, there has to be a reason.